Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.

The findings are published online in Cancer. A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec.